In enzymology, as in organic chemistry, many transformations revolve around the chemistry of the carbonyl group. A carbonyl group is electrophilic -how can it be made more so? Hydrogens next to a carbonyl group have a reduced pK, -how can this reactivity be promoted? Nature has found several ways to address these mechanistic challenges, the most important of which is the use of imines. Studies on two enzymes which exploit imines are described: one in which the carbonyl component is supplied by substrate and the second, less usual case, in which the carbonyl group is part of the protein backbone.
Dehydroquinase
Dehydroquinase is the third enzyme on the shikimate pathway, the biosynthetic route to the aromatic amino acids and many other aromatic metabolites [l] . T h e shikimate pathway is present in micro-organisms, fungi and plants, but not in mammals. Because over 20% of the carbon flux in a plant goes through this pathway, it is not surprising that it has been a target for herbicides. Glyphosate, the most successful herbicide ever developed, works by inhibiting the sixth enzyme on the pathway, 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase.
Dehydroquinase catalyses the reversible conversion of 3-dehydroquinate 1 into 3-dehydroshikimate 4 (Scheme la), and is a potential her-
Scheme I (a) Proposed mechanisms of type I and type II dehydroquinases, and (b)
inactivation of type I dehydroquinase by 2-bromodehydroquinate bicide target (or antibiotic or fungicide target). However, any inhibition strategy must take into account the complexities of the enzymology. In the early 1990s it became apparent from the accumulation of protein sequences that there must be two distinct forms of dehydroquinase, now known as type I and type I1 [Z] . There are many differences between type I and type I1
enzymes. Type I enzymes, typified by the Escherichia coli enzyme, are dimeric with subunit M , of about 27000. Type I1 enzymes have a smaller subunit M,, typically 12000-18000, but can be dodecameric. Type I enzymes are always associated with the shikimate pathway, whereas type I1 enzymes are found on either the shikimate or quinate pathways. The quinate pathway is a catabolic pathway used by fungi to metabolize quinic acid as a carbon source. Type I dehydroquinases all have a highly conserved lysine at the active site that is involved in imine formation (Scheme la). When type I dehydroquinase is incubated with 3-dehydroquinate and sodium borohydride is then added the enzyme is irreversibly inhibited. We have trapped this reductively modified enzyme and used electrospray mass spectrometry (ESMS) to show that it is the enzyme-product adduct 3 that is being trapped [3] . If the borohydride is omitted the enzyme-product adduct can be seen directly by ESMS albeit at low abundance.
An intriguing aspect of the type I-catalysed dehydration of 2-dehydroquinate is the overall syn stereochemistry. The initial deprotonation involves the loss of the less acidic equatorial (proR) C2 hydrogen of dehydroquinate. It has been proposed that the initially formed imine 2 is somehow distorted to align the proR hydrogen with the 7r system of the iminium bond, enhancing its acidity. Deprotonation by a base (almost certainly by His-143) forms the enamine. The conjugate acid of the base is then well placed to protonate the hydroxyl group lost at C1.
The syn stereochemistry of the elimination is thus associated with the imine mechanism. The question then arises as to what is the stereochemical course of the reaction catalysed by the type I1 enzyme, because there is no conserved lysine in the sequence and so the mechanism is unlikely to involve imine formation. It seemed probable that the stereochemistry would be trans, as this is the stereochemistry observed in the acid-or base-catalysed conversion of 3-dehydroquinate into 3-dehydroshikimate [4] .
We investigated the stereochemistry of the transformation by incubating dehydroquinate in H 2 0 with either the type I or the type I1 dehydroquinase alone in a 'H-NMR spectroscopy experiment. As the equilibrium for the transformation is 15:l in favour of product, 3-dehydroshikimate forms rapidly and reversibly. The signal for the hydrogen on C2 of 4 is easily observed. In the presence of either dehydroquinase alone, the reversible formation of 3-dehydroshikimate in 'H20 cannot result in incorporation of 'H into the C2 position. However, if the experiment is repeated in the presence of both enzymes, and if the stereochemical courses of the two enzymic reactions are different, it is possible to deuterate the C2 position of 3-dehydroshikimate. This occurs, for example, if 3-dehydroshikimate is hydrated by a type I enzyme, thus putting a 'H into the 2-proR position of 3-dehydroquinate. This species is then dehydrated by a type I1 enzyme, which removes the 2-pros hydrogen. A steady decrease with time in the 'H signal of 3-dehydroshikimate was observed when this experiment was performed with a mixture of enzymes, proving that the enzymes do indeed follow opposite stereochemical courses [5] .
Based initially on stereochemical considerations and the knowledge of the non-enzymic reaction, a mechanism involving an enol or enolate chemistry for the type I1 enzyme was assumed (Scheme la). This was subsequently supported by the results of numerous kinetic studies [6] . These studies showed an unexpected pH dependence for both k,,, and K,. Both increased steeply at higher pH; this was interpreted in terms of the deprotonation of an arginine residue at the active site leading to faster deprotonation of the substrate but also to less efficient binding.
From these mechanistic and stereochemical considerations, we adopted a simple model for the structure of the active sites of the type I and type I1 dehydroquinases. This was used as the basis for the rational design of type-specific inhibitors. (ZR)-Z-Bromodehydroquinate 5 has an equatorial bromine atom which should stabilize the enolate intermediate in the type I1 dehydroquinase mechanism, and yet should interfere with binding to the type I enzyme.
(ZR)-Z-Bromodehydroquinate was synthesized in six steps from quinic acid in 29% overall yield [7] . It was expected that substitution with such a large group would affect the specificity of type I1 dehydroquinase for 5 relative to that for 3-dehydroquinate. However, the k,,,/K,,, was almost unchanged, and (2R)-Z-bromodehydroquinate was an excellent substrate for type I1 dehydroquinase. Not surprisingly (2R)-Z-bromodehydroquinate was not a substrate for type I dehydroquinase; nor was it surprising that it was only a modest competitive inhibitor. What was unexpected was that it would be an irreversible inhibitor. Incubation of 5 with type I dehydroquinase resulted in slow irreversible inhibition. The mechanism of this inhibition is not fully understood; however, some interesting results have been obtained by studying the modified enzyme by ESMS, in which a new peak corresponding to the addition of 126 units to the subunit M , was seen. This is somewhat less than expected if inhibition simply involved loss of the bromine atom. The observed adduct is explained if the imine intermediate undergoes decarboxylative loss of bromide to form compound 6 (Scheme lb). This may be facilitated by the postulated change in conformation of the substrate on binding to the enzyme. Interestingly, treatment of type I dehydroquinase with 2-bromodehydroshikimate (the product of the reaction of 5 with type I1 dehydroquinase) also resulted in irreversible inactivation of the type I enzyme, but formation of a different adduct. The increase in relative molecular mass is that expected from simple loss of bromide from the enzyme-inhibitor adduct and can most easily be explained by an addition-elimination mechanism.
(2R)-Z-Brornodehydroquinate is thus a substrate for the type I1 enzyme and an inhibitor of the type I enzyme. Very recently studies have been directed at finding inhibitors which show the reverse specificity.
Although not yet in the public domain the crystal structures of both enzymes have now been solved by research groups in Scotland, U.K. These structures will enable us to refine our design and make inhibitors that are more potent.
Aspartate decarboxylase
Aspartate decarboxylase catalyses the conversion of aspartate 7 into p-alanine 8 (Scheme 2). This is an important part of the pathway to vitamin B5, pantothenate -the precursor of coenzyme A. In collaboration with Dr. Alison Smith (Plant Sciences, Cambridge, U. K.) we have been interested in the pantothenate pathway for several years and published the first sequence of a pantothenate pathway enzyme gene, panB, which encodes ketopantoate hydroxymethyl transferase [8] . We have also reported experiments in which pea seedlings were fed with [I4C]valine, the precursor of the first intermediate on the pantothenate pathway, a-ketovaleric acid [9] . This study provided some of the earliest evidence for the pathway in plants.
The E. coli gene for aspartate decarboxylase is pa&. It is part of an operon that includes panB and panC (which encodes pantothenate synthease) [lo] . We used PCR to isolate the gene and set up an overexpression system that yields multi milligram amounts of protein [ll] . The protein is a tetramer of M , 56 000, which is difficult to dissociate into subunits, typically requiring heating with 2% SDS at 100°C for several minutes.
The most interesting aspect of the aspartate decarboxylase mechanism is the involvement of a pyruvoyl group which is integral to the protein. 
Volume 26 what appears to be a common mechanism using an integral pyruvoyl group. However, histidine decarboxylase is a trimeric protein with a subunit M, of 34000, whereas aspartate decarboxylase is tetrameric with a subunit M , of 13 834. Furthermore, there appears to be no sequence homology between the proteins, except for the presence of a serine which is the precursor to the pyruvoyl P U P . The mechanism for formation of the pyruvoyl group in aspartate decarboxylase, based on the proposed mechanism for histidine decarboxylase, is shown in Scheme 3. The first step in formation of the pyruvoyl group is an N -0 acyl shift. For aspartate decarboxylase this converts the amide bond between Gly-24 and Ser-25 in the proprotein 9 into an ester bond 10. The next step is removal of the C-a proton of Ser-25 in a step which eliminates the glycine carboxylate. This cleaves the proprotein into a smaller P-chain, terminating in Gly-24, and a larger a-chain 11 starting with a primary enamine derived from Ser-25. It is assumed that the enamine then hydrolyses to form the pyruvoyl residue 12. The best evidence for this overall mechanism comes from an experiment on histidine decarboxylase in which it was shown that an I8O label in the serine hydroxyl of the proprotein was transferred to the carboxylate on the other side of the cleavage junction (equivalent to Gly-24 in aspartate decarboxylase) [14] .
Immediately after purification, aspartate decarboxylase was already partially processed.
Full-length proprotein, a-and fl-chains were all seen on high-resolution SDS/PAGE. When the protein was heated at 50°C the intensity of the band corresponding to proprotein decreased as more a-and fl chains were formed. After about 50 h no proprotein remained. When this 'fully processed' protein was studied by ESMS, the expected peaks at M, 2834 (fl-chain) and M , 11 000 (a-chain) were observed. However, there was also a peak at M , 11 018 (due to the a-chain terminating in a serine), which appears to be derived by degradation of the ester intermediate. Furthermore, quantitative studies based on fluorescent modification of the pyruvoyl group, or degradation of the protein to release pyruvate, showed that there are only three pyruvoyl groups per tetramer. This result was unexpected. It was speculated that perhaps the overexpression system was lacking some additional factor that was involved in processing of aspartate decarboxylase in vivo.
In collaboration with Professor Tom Blundell (Biochemistry, Cambridge, U.K.) aspartate decarboxylase has been crystallized and the structure solved to 2.2A resolution [14a] . As expected the structure is tetrameric. It is mushroom-shaped, made of the four subunits which can each be likened to a 'wrist' and 'fist'. The wrist of each subunit comprises two strands which combine to form a P-cylinder at the base of the structure. The active sites are between pairs of fists. Although the molecule is tetrameric, the structure does not have complete four-fold symmetry. Three of the subunits are identical and one is different. We have interpreted the electron density to show that in three of the active sites the polypeptide chain is cleaved and there is a pyruvoyl group, while in the fourth the chain is uncleaved, but bent into a tight loop. Aspartate was modelled into the pyruvoylcontaining active site, as an imine with the pyruvoyl group (Scheme 2). In this model there is a very good interaction between the guanidinium group of Arg-54 and the 8-carboxylate of aspartate. This interaction is presumed to be important for substrate specificity. The a-carboxyl is in a hydrophobic area due to the aromatic ring of Tyr-58 the pyruvoyl methyl group. This environment may promote the decarboxylation reaction by destabilizing the initial negative charge on the carboxylate.
Our first assumption was that the uncleaved proprotein in the fourth active site was simply the unchanged polypeptide 9 (Scheme 3). However, when we attempted to model this on to the electron density map, the model did not refine well. The amide bond between Gly-24 and Ser-25 was not planar and there were several Ramachandran outliers. A much better fit with the electron density map was found for the ester 10. Part of the reason for the better fit is the reduced need for planarity around the ester bond, and the slightly longer backbone due to the replacement of N H with CHZ-O.
The structure 10 was very surprising, not least because an ester bond has not previously been detected in the polypeptide backbone of a protein. The discovery was also extremely topical, given the growing interest in, and understanding of, protein splicing [ 151. Protein splicing occurs when RNA in an intron is translated rather than being spliced out in the formation of mRNA. The additional protein encoded by this RNA is called an intein. The intein is autocatalytically excised by a mechanism in which the first and last intermediates are proposed to be esters.
Why is aspartate decarboxylase not fully processed to have a pyruvoyl group at each of the four active sites in the tetramer? Histidine decarboxylase is trimeric and has a pyruvoyl group in each active site. One possible explanation starts by assuming that the proprotein assembles initially to form a symmetrical tetramer. The reaction to cleave the proprotein and form the pyruvoyl group then occurs at a subunit interface. This reaction almost certainly requires the participation of side chains from the adjacent subunit. As a result of the cleavage reaction in one active site, the pyruvoyl group forms and the cleaved structure relaxes slightly. It is then proposed that the next cleavage reaction occurs at an adjacent subunit interface, but that this cleavage reaction is slowed by the minor structural changes that occur as a result of the cleavage of the first subunit. It is then proposed that the next cleavage occurs at the next interface round the tetramer, but is further slowed as now two subunits have relaxed. The propagation of this negatively cooperative mechanism means that the third cleavage is even slower. The fourth cleavage reaction is the first one to involve an interface where the adjacent subunit has already been cleaved. However, if the cleaved subunit has changed conformation slightly, it may not present the catalytic groups necessary to participate properly in the final processing reaction, resulting in the ester 10 being kinetically trapped. Consistent with this proposal, the crystal structure shows that there is no good basic residue close to the Ser-25 C-a proton. The nearest likely candidate is the phenolic group in Tyr-58, which is over 5 8, away.
The above mechanism is speculative based on the crystal structure (the end point) and our limited knowledge of the rate of processing. It can be tested if the various forms of the tetramer fixed at particular stages in the processing sequence can be isolated. This work is now in progress. It has highlighted the point that although we understand superficially how the pyruvoyl group is formed, there are really many unanswered questions. For example does the processing of the tetrameric proprotein involve complete formation of a pyruvoyl at one active site, before the ester is formed at the next, or could the tetraester be an intermediate? [7] , while Ins(1,4,5)P3 causes the release of Ca2+ from an intracellular store, an action which also moduAbbreviations used: DAG, diacyl glycerol; Ins( 1,4,5) P3, inositol 1,4,5-triphosphate; IMPase, inositol monophosphatase; InslP, myo-inositol 1-monophosphate; Ins3P, myo-inositol 3-monophosphate; Ins4P, myoinositol 4-monophosphate. 'To whom correspondence should be addressed.
lates the activity of certain proteins [8] . Brain cells vary in their ability to take up free inositol [3, 9] and the major pathway for replenishing intracellular inositol levels appears to depend on a series of phosphatases which exist to sequentially hydrolyse Ins( 1,4,5)P3 and other inositol polyphosphates via the bisphosphates to give inositol 1-and 4-monophosphates (InslP, Ins4P), the substrates for IMPase. In the only other available route, ~-1 n s 3 P (iA-InslP), also a substrate for IMPase, is produced in de novo biosynthesis from glucose 6-phosphate through the action of inositol synthase [3] . Thus, IMPase plays a pivotal role in being able to process each of these inositol monophosphates to give the inositol required for the resynthesis of the secondary messengers. T h e effect of blocking the action of the enzyme with the inhibitor Li' cation leads to the accumulation of inositol monophosphates and to the depletion of free inositol in brain cells [10, 11] and, since these results were first described, several groups have suggested that the enzyme might be the target for Li' therapy in
